0

Close
 
Upcoming Allied Market Research
2023
Hunter’s Syndrome Market

Hunter’s Syndrome Market

by Treatment Type (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), Others), by Route of Administration (Oral, Parenteral, Others) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A10499
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Hunter’s Syndrome Market

Request Now !

Hunter’s syndrome mucopolysaccharidosis type II (MPS II) is a rare genetic disorder in which large sugar molecules called glycosaminoglycans (GAGs) or mucopolysaccharides are produced in body tissues. It is observed to be a form of lysosomal storage disease. Hunter’ssyndrome is caused by the deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The lack of this enzyme causes heparan sulfate and dermatan sulfate to accumulate in all body tissues. Hunter’ssyndrome is the only MPS syndrome to exhibit X-linked recessive inheritance. The symptoms of this syndrome are abdominal hernias, ear infections, runny nose, and cold. As the buildup of GAGs continues throughout the cells of the body, signs of MPS II become more visible.

Hunter‐™s-Syndrome

COVID-19 scenarioanalysis

Key pharmaceutical and biotechnological companies have grouped together with governments such that they meet the current demand for medical supplies throughout the globe.Increase in demand has been witnessed for drugs, which presentspotential opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs.There are around 115 vaccine candidates and other 155 molecules that are advanced such that the research and development pipelines are updated in the coming years. The commonly used drugs such as hydroxychloroquine have seenhugeboost in demand for the management of COVID-19.Due to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expectedto grow significantly in the coming years.

Top impacting factors: market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the industry include introduction of novel therapies, which would propel the growth of the industry in the coming years.Increase in increase in government initiatives and rise in awareness about Hunter’s syndrome fuelthe market growth during the forecast period.In addition, surge in number of mergers and acquisitions boosts the market growth in the upcoming years. However, implementation of stringent regulations for the manufacturing of drugs may hinder the growth of the industry.

Surge in number of patients

According to the National MPS Society, Hunter’s syndrome is a rare condition affecting 1 in 100,000 to 1 in 170,000, primarily males.Females may be carriers of the gene for MPS II. Although rare, MPS II has been diagnosed in girls. If the mother is a carrier, there is a 50% chance that any boy born will have the disease.

Sisters and maternal aunts of a person with MPS II may be carriers of the disease and would also have a 50% chance of passing the syndrome to son.Increase in the of patient population would positively impact the growth of the industry in the near future.

Surge in number of mergers and acquisitions

Increase in the number of mergers and acquisitions is anticipated toboost the industrygrowth in the coming years. For instance, in July 2014, ArmaGen, a privately held biotechnology company, announced that it had entered into a worldwide licensing and collaboration agreement with Shire Plc.to develop AGT-182, an investigational enzyme replacement therapy (ERT) for potential treatment of both the central nervous system (CNS) and somatic (body-related) manifestations of Hunter’s syndrome.

In 2014, Shire agreed a deal to buy the U.S.Company, Lumena Pharmaceuticals for $260m, bolstering its pipeline of rare disease candidates. Shire had itself been the subject of merger speculation with Allergan. Furthermore, buying Lumena would help provide two drugs in mid-stage clinical trials for rare liver diseases that will complement its own gastrointestinal drug portfolio. LUM001 and LUM002 are both inhibitors of the apical sodium-dependent bile acid transporter, or ASBT, and are being tested as treatments for cholestatic liver diseases, which occur when the flow of bile from the liver to the duodenum is reduced or blocked. ASBT is responsible for recycling bile acids back to the liver.

Key benefits of the report:

  • This study presents the analytical depiction of the global Hunter’s syndrome industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Hunter’s syndrome market share.
  • The current market is quantitatively analyzed to highlight the Hunter’s syndromemarket growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the Hunter’s syndromemarket.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Hunter’s syndrome market research report:

  • Which are the leading players active in the Hunter’s syndrome market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in tasking further strategic steps?

 Hunter’s Syndrome Market Report Highlights

Aspects Details
By Treatment Type
  • Enzyme Replacement Therapy (ERT)
  • Hematopoietic Stem Cell Transplant (HSCT)
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Takeda Pharmaceutical Company,, Inventiva S.A.,, ArmaGen Inc.,, JCR Pharmaceuticals Co Ltd.,, Denali Therapeutics Inc.,, RegenxBio Inc.,, Regenxbio, Sangamo Therapeutics, Inc.,, GC Pharma,, Bioasis Technologies Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: HUNTER’S SYNDROME MARKET, BY TREATMENT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment Type

    • 4.2. Enzyme Replacement Therapy (ERT)

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Hematopoietic Stem Cell Transplant (HSCT)

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: HUNTER’S SYNDROME MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Parenteral

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: HUNTER’S SYNDROME MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Retail Pharmacy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Online Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: HUNTER’S SYNDROME MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Treatment Type

      • 7.2.3. Market Size and Forecast, By Route Of Administration

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Hunter’s Syndrome Market

        • 7.2.6.1. Market Size and Forecast, By Treatment Type
        • 7.2.6.2. Market Size and Forecast, By Route Of Administration
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Hunter’s Syndrome Market

        • 7.2.7.1. Market Size and Forecast, By Treatment Type
        • 7.2.7.2. Market Size and Forecast, By Route Of Administration
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Hunter’s Syndrome Market

        • 7.2.8.1. Market Size and Forecast, By Treatment Type
        • 7.2.8.2. Market Size and Forecast, By Route Of Administration
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Treatment Type

      • 7.3.3. Market Size and Forecast, By Route Of Administration

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Hunter’s Syndrome Market

        • 7.3.6.1. Market Size and Forecast, By Treatment Type
        • 7.3.6.2. Market Size and Forecast, By Route Of Administration
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Hunter’s Syndrome Market

        • 7.3.7.1. Market Size and Forecast, By Treatment Type
        • 7.3.7.2. Market Size and Forecast, By Route Of Administration
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Hunter’s Syndrome Market

        • 7.3.8.1. Market Size and Forecast, By Treatment Type
        • 7.3.8.2. Market Size and Forecast, By Route Of Administration
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Hunter’s Syndrome Market

        • 7.3.9.1. Market Size and Forecast, By Treatment Type
        • 7.3.9.2. Market Size and Forecast, By Route Of Administration
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Hunter’s Syndrome Market

        • 7.3.10.1. Market Size and Forecast, By Treatment Type
        • 7.3.10.2. Market Size and Forecast, By Route Of Administration
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Hunter’s Syndrome Market

        • 7.3.11.1. Market Size and Forecast, By Treatment Type
        • 7.3.11.2. Market Size and Forecast, By Route Of Administration
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Hunter’s Syndrome Market

        • 7.3.12.1. Market Size and Forecast, By Treatment Type
        • 7.3.12.2. Market Size and Forecast, By Route Of Administration
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Treatment Type

      • 7.4.3. Market Size and Forecast, By Route Of Administration

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Hunter’s Syndrome Market

        • 7.4.6.1. Market Size and Forecast, By Treatment Type
        • 7.4.6.2. Market Size and Forecast, By Route Of Administration
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Hunter’s Syndrome Market

        • 7.4.7.1. Market Size and Forecast, By Treatment Type
        • 7.4.7.2. Market Size and Forecast, By Route Of Administration
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Hunter’s Syndrome Market

        • 7.4.8.1. Market Size and Forecast, By Treatment Type
        • 7.4.8.2. Market Size and Forecast, By Route Of Administration
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Hunter’s Syndrome Market

        • 7.4.9.1. Market Size and Forecast, By Treatment Type
        • 7.4.9.2. Market Size and Forecast, By Route Of Administration
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Hunter’s Syndrome Market

        • 7.4.10.1. Market Size and Forecast, By Treatment Type
        • 7.4.10.2. Market Size and Forecast, By Route Of Administration
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Hunter’s Syndrome Market

        • 7.4.11.1. Market Size and Forecast, By Treatment Type
        • 7.4.11.2. Market Size and Forecast, By Route Of Administration
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Hunter’s Syndrome Market

        • 7.4.12.1. Market Size and Forecast, By Treatment Type
        • 7.4.12.2. Market Size and Forecast, By Route Of Administration
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Hunter’s Syndrome Market

        • 7.4.13.1. Market Size and Forecast, By Treatment Type
        • 7.4.13.2. Market Size and Forecast, By Route Of Administration
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Hunter’s Syndrome Market

        • 7.4.14.1. Market Size and Forecast, By Treatment Type
        • 7.4.14.2. Market Size and Forecast, By Route Of Administration
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Treatment Type

      • 7.5.3. Market Size and Forecast, By Route Of Administration

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Hunter’s Syndrome Market

        • 7.5.6.1. Market Size and Forecast, By Treatment Type
        • 7.5.6.2. Market Size and Forecast, By Route Of Administration
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Hunter’s Syndrome Market

        • 7.5.7.1. Market Size and Forecast, By Treatment Type
        • 7.5.7.2. Market Size and Forecast, By Route Of Administration
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Hunter’s Syndrome Market

        • 7.5.8.1. Market Size and Forecast, By Treatment Type
        • 7.5.8.2. Market Size and Forecast, By Route Of Administration
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Hunter’s Syndrome Market

        • 7.5.9.1. Market Size and Forecast, By Treatment Type
        • 7.5.9.2. Market Size and Forecast, By Route Of Administration
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Hunter’s Syndrome Market

        • 7.5.10.1. Market Size and Forecast, By Treatment Type
        • 7.5.10.2. Market Size and Forecast, By Route Of Administration
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Hunter’s Syndrome Market

        • 7.5.11.1. Market Size and Forecast, By Treatment Type
        • 7.5.11.2. Market Size and Forecast, By Route Of Administration
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Takeda Pharmaceutical Company,

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. GC Pharma,

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. JCR Pharmaceuticals Co Ltd.,

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. RegenxBio Inc.,

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Sangamo Therapeutics, Inc.,

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. ArmaGen Inc.,

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Inventiva S.A.,

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Denali Therapeutics Inc.,

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Bioasis Technologies Inc.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Regenxbio

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HUNTER’S SYNDROME MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL HUNTER’S SYNDROME MARKET FOR ENZYME REPLACEMENT THERAPY (ERT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL HUNTER’S SYNDROME MARKET FOR HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL HUNTER’S SYNDROME MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL HUNTER’S SYNDROME MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL HUNTER’S SYNDROME MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL HUNTER’S SYNDROME MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL HUNTER’S SYNDROME MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL HUNTER’S SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL HUNTER’S SYNDROME MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL HUNTER’S SYNDROME MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL HUNTER’S SYNDROME MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL HUNTER’S SYNDROME MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL HUNTER’S SYNDROME MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA HUNTER’S SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 19. U.S. HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 20. U.S. HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 21. U.S. HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 22. CANADA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 23. CANADA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. CANADA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE HUNTER’S SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. ITALY HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. ITALY HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. ITALY HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. UK HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 45. UK HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 46. UK HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC HUNTER’S SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 57. CHINA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 58. CHINA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 59. CHINA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. INDIA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 64. INDIA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 65. INDIA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA HUNTER’S SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 97. UAE HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 98. UAE HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 99. UAE HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA HUNTER’S SYNDROME, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA HUNTER’S SYNDROME, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA HUNTER’S SYNDROME, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 106. TAKEDA PHARMACEUTICAL COMPANY,: KEY EXECUTIVES
  • TABLE 107. TAKEDA PHARMACEUTICAL COMPANY,: COMPANY SNAPSHOT
  • TABLE 108. TAKEDA PHARMACEUTICAL COMPANY,: OPERATING SEGMENTS
  • TABLE 109. TAKEDA PHARMACEUTICAL COMPANY,: PRODUCT PORTFOLIO
  • TABLE 110. TAKEDA PHARMACEUTICAL COMPANY,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. GC PHARMA,: KEY EXECUTIVES
  • TABLE 112. GC PHARMA,: COMPANY SNAPSHOT
  • TABLE 113. GC PHARMA,: OPERATING SEGMENTS
  • TABLE 114. GC PHARMA,: PRODUCT PORTFOLIO
  • TABLE 115. GC PHARMA,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. JCR PHARMACEUTICALS CO LTD.,: KEY EXECUTIVES
  • TABLE 117. JCR PHARMACEUTICALS CO LTD.,: COMPANY SNAPSHOT
  • TABLE 118. JCR PHARMACEUTICALS CO LTD.,: OPERATING SEGMENTS
  • TABLE 119. JCR PHARMACEUTICALS CO LTD.,: PRODUCT PORTFOLIO
  • TABLE 120. JCR PHARMACEUTICALS CO LTD.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. REGENXBIO INC.,: KEY EXECUTIVES
  • TABLE 122. REGENXBIO INC.,: COMPANY SNAPSHOT
  • TABLE 123. REGENXBIO INC.,: OPERATING SEGMENTS
  • TABLE 124. REGENXBIO INC.,: PRODUCT PORTFOLIO
  • TABLE 125. REGENXBIO INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. SANGAMO THERAPEUTICS, INC.,: KEY EXECUTIVES
  • TABLE 127. SANGAMO THERAPEUTICS, INC.,: COMPANY SNAPSHOT
  • TABLE 128. SANGAMO THERAPEUTICS, INC.,: OPERATING SEGMENTS
  • TABLE 129. SANGAMO THERAPEUTICS, INC.,: PRODUCT PORTFOLIO
  • TABLE 130. SANGAMO THERAPEUTICS, INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. ARMAGEN INC.,: KEY EXECUTIVES
  • TABLE 132. ARMAGEN INC.,: COMPANY SNAPSHOT
  • TABLE 133. ARMAGEN INC.,: OPERATING SEGMENTS
  • TABLE 134. ARMAGEN INC.,: PRODUCT PORTFOLIO
  • TABLE 135. ARMAGEN INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. INVENTIVA S.A.,: KEY EXECUTIVES
  • TABLE 137. INVENTIVA S.A.,: COMPANY SNAPSHOT
  • TABLE 138. INVENTIVA S.A.,: OPERATING SEGMENTS
  • TABLE 139. INVENTIVA S.A.,: PRODUCT PORTFOLIO
  • TABLE 140. INVENTIVA S.A.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. DENALI THERAPEUTICS INC.,: KEY EXECUTIVES
  • TABLE 142. DENALI THERAPEUTICS INC.,: COMPANY SNAPSHOT
  • TABLE 143. DENALI THERAPEUTICS INC.,: OPERATING SEGMENTS
  • TABLE 144. DENALI THERAPEUTICS INC.,: PRODUCT PORTFOLIO
  • TABLE 145. DENALI THERAPEUTICS INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. BIOASIS TECHNOLOGIES INC.: KEY EXECUTIVES
  • TABLE 147. BIOASIS TECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 148. BIOASIS TECHNOLOGIES INC.: OPERATING SEGMENTS
  • TABLE 149. BIOASIS TECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 150. BIOASIS TECHNOLOGIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. REGENXBIO: KEY EXECUTIVES
  • TABLE 152. REGENXBIO: COMPANY SNAPSHOT
  • TABLE 153. REGENXBIO: OPERATING SEGMENTS
  • TABLE 154. REGENXBIO: PRODUCT PORTFOLIO
  • TABLE 155. REGENXBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HUNTER’S SYNDROME MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HUNTER’S SYNDROME MARKET
  • FIGURE 3. SEGMENTATION HUNTER’S SYNDROME MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HUNTER’S SYNDROME MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHUNTER’S SYNDROME MARKET
  • FIGURE 11. HUNTER’S SYNDROME MARKET SEGMENTATION, BY BY TREATMENT TYPE
  • FIGURE 12. HUNTER’S SYNDROME MARKET FOR ENZYME REPLACEMENT THERAPY (ERT), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. HUNTER’S SYNDROME MARKET FOR HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. HUNTER’S SYNDROME MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. HUNTER’S SYNDROME MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 16. HUNTER’S SYNDROME MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. HUNTER’S SYNDROME MARKET FOR PARENTERAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. HUNTER’S SYNDROME MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. HUNTER’S SYNDROME MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 20. HUNTER’S SYNDROME MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. HUNTER’S SYNDROME MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. HUNTER’S SYNDROME MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. HUNTER’S SYNDROME MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: HUNTER’S SYNDROME MARKET
  • FIGURE 30. Top player positioning, 2022
  • FIGURE 31. TAKEDA PHARMACEUTICAL COMPANY,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. TAKEDA PHARMACEUTICAL COMPANY,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. TAKEDA PHARMACEUTICAL COMPANY,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. GC PHARMA,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. GC PHARMA,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. GC PHARMA,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. JCR PHARMACEUTICALS CO LTD.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. JCR PHARMACEUTICALS CO LTD.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. JCR PHARMACEUTICALS CO LTD.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. REGENXBIO INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. REGENXBIO INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. REGENXBIO INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. SANGAMO THERAPEUTICS, INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. SANGAMO THERAPEUTICS, INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. SANGAMO THERAPEUTICS, INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. ARMAGEN INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. ARMAGEN INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. ARMAGEN INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. INVENTIVA S.A.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. INVENTIVA S.A.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. INVENTIVA S.A.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. DENALI THERAPEUTICS INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. DENALI THERAPEUTICS INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. DENALI THERAPEUTICS INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. BIOASIS TECHNOLOGIES INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. BIOASIS TECHNOLOGIES INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. BIOASIS TECHNOLOGIES INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. REGENXBIO: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. REGENXBIO: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. REGENXBIO: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Hunter’s Syndrome Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers